The Latest Analyst Ratings for Biogen
Portfolio Pulse from Benzinga Insights
Biogen (NASDAQ:BIIB) has received a mix of analyst ratings within the last quarter, with 1 bullish, 6 somewhat bullish, and 2 indifferent ratings. The average 12-month price target among 9 analysts is $316.67, which is a 3.03% decrease from the previous target of $326.57. The high target is $373.00 and the low target is $239.00. Analyst ratings are based on financial analysis and forecasts, and while they are expert opinions, they are still subjective.
December 07, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biogen has a majority of somewhat bullish ratings and a slight decrease in the average price target, suggesting a cautiously optimistic outlook from analysts.
The mix of analyst ratings for Biogen indicates a generally positive but cautious sentiment. The slight decrease in the average price target may temper expectations for short-term growth, but the absence of bearish ratings suggests stability. Analyst ratings can influence investor perception, but the actual impact on the stock price in the short term is often limited unless accompanied by significant news or changes in the company's fundamentals.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100